#United States #Stockholm #Multiple Myeloma #DARZALEX FASPRO #TALVEY

Overview of Recent Clinical Findings

Recent clinical data highlights the efficacy of TALVEY® (talquetamab-tgvs) in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), particularly in treating patients with relapsed or refractory multiple myeloma. Conducted by Johnson & Johnson, the MonumenTAL-3 study marks a significant advancement in the field, showcasing the potential for improved treatment outcomes for this challenging disease.

Key Findings from MonumenTAL-3 Study

The study indicated that patients who received TALVEY® combined with DARZALEX FASPRO®, with or without the addition of pomalidomide, experienced a notable progression-free survival (PFS) of up to 81% at the 24-month mark. Additionally, the overall survival (OS) rate reached up to 89%, demonstrating a significant improvement compared to the conventional treatment regimen that includes DARZALEX FASPRO®, pomalidomide, and dexamethasone (DPd).

Specifically, the results showed a 72% reduction in the risk of disease progression or death, and a 53% reduction in the risk of death versus standard treatment options. These encouraging outcomes were presented at the 2026 European Hematology Association Annual Meeting and published in The New England Journal of Medicine, adding credibility to the findings.

Importance of Earlier Treatment Options

As indicated by medical experts, these results underscore the critical need for introducing effective treatments earlier in the treatment journey for patients. Dr. Peter Voorhees, a prominent hematologist and oncologist, commented on the significance of TALVEY® working alongside DARZALEX FASPRO in earlier treatment lines, emphasizing the potential for improved patient outcomes at a critical time in treatment progression.

Dr. Yusri Elsayed, Global Therapeutic Head at Johnson & Johnson, also noted that these results support the company’s strategy to advance innovative treatments within the existing portfolio of multiple myeloma therapies, aiming to provide personalized treatment options tailored to specific patient needs.

TALVEY®: A Unique Mechanism of Action

TALVEY® targets GPRC5D, a protein present on multiple myeloma cells, which differentiates it from other therapeutic agents like BCMA. Importantly, its targeting mechanism allows it to spare healthy B-cells, potentially reducing side effects while effectively targeting malignant cells. This unique approach provides a new frontier in treating multiple myeloma, paving the way for more efficacious and safer treatment protocols.

Clinical Trial Insights and Safety Profiles

The MonumenTAL-3 study observed improvements not only in progression-free survival but also across various secondary endpoints, including overall response rates and minimal residual disease negativity after two years of follow-up. Across the trial population of 864 patients, significant enhancements were noted in overall response rates and disease control metrics, indicating a promising therapy for these patients.

The safety profile associated with the TALVEY® and DARZALEX FASPRO® combination was aligned with the known safety profiles for each component of the treatment regimen, demonstrating manageable adverse events and a lower incidence of severe infections.

Future Directions

Following the promising findings, Johnson & Johnson is actively working with regulatory authorities worldwide to expedite the availability of TALVEY® in conjunction with DARZALEX FASPRO® to eligible patients. Submissions for supplemental Biologics License Applications have been made to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), aiming to bring this breakthrough therapeutic combination to patients as swiftly as possible.

In conclusion, as a third positive study in recent months for Johnson & Johnson’s bispecific portfolio, the MonumenTAL-3 findings represent a decisive moment in the fight against multiple myeloma, with clinical evidence advocating for the integration of TALVEY® and DARZALEX FASPRO® into earlier treatment modalities, ultimately aiming to enhance patient survival rates and quality of life in this continually evolving field.